A Phase 1B Study of PTC596 in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Dacarbazine (Primary) ; PTC 596 (Primary)
- Indications Leiomyosarcoma
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 06 Sep 2019 Planned End Date changed from 16 Dec 2020 to 20 Dec 2020.
- 06 Sep 2019 Planned primary completion date changed from 16 Dec 2020 to 20 Dec 2020.
- 02 May 2019 According to a PTC Therapeutics media release, the company expects to fully enroll in this study by the end of 2019.